Sermorelin
Research use only.
High-purity research-grade Sermorelin
Sermorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) widely studied for its ability to stimulate endogenous growth hormone secretion. As a 29-amino-acid fragment of the natural GHRH peptide, Sermorelin is commonly explored in research involving growth hormone regulation, recovery, body composition, and age-related hormonal decline. It is often investigated as a physiological approach to supporting pulsatile growth hormone release.
Product overview
Sermorelin functions by binding to growth hormone-releasing hormone receptors in the anterior pituitary gland, promoting the natural secretion of growth hormone in a pulsatile pattern. Research involving Sermorelin has focused on its role in restoring or enhancing endogenous GH activity without directly supplying exogenous growth hormone, making it a key compound in endocrine regulation studies.
Key research features
Supports endogenous growth hormone release: Studies indicate Sermorelin may increase natural GH secretion, which in turn can elevate IGF-1 levels and support downstream anabolic and regenerative processes. This mechanism has made it widely studied in anti-aging and hormone optimization research models.
Recovery and tissue repair: Research suggests Sermorelin may support muscle recovery, connective tissue repair, and cellular regeneration through enhanced growth hormone signaling. Experimental findings highlight interest in its role in post-stress and post-injury recovery pathways.
Body composition and metabolic research: Sermorelin has been investigated for its potential to support lean muscle maintenance, fat metabolism, and improved nutrient partitioning through GH-mediated effects on energy utilization.
Age-related hormonal decline research: Early studies have explored Sermorelin’s potential utility in models of age-associated growth hormone reduction, focusing on restoring more youthful GH pulsatility and endocrine balance.
Sermorelin Suggested Use:
Typical Dose: 0.2–0.5 mg per day
Route: Subcutaneous injection
Frequency: Once daily (typically at night)
Duration: 8–12 weeks, or as recommended by a healthcare professional